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Introduction:We evaluated the results of postoperative mediastinal
radiotherapy (MRT) for invasive thymoma and low-dose entire
hemithorax radiotherapy (EHRT) for pleural dissemination.
Methods: Sixty patients were treated with a nearly uniform policy.
Generally, we administered 30 to 40 Gy MRT after surgery at 2 Gy
daily fractions for Masaoka stage II tumors or suspected residual
diseases, and 50 to 55 Gy MRT for stage III tumors and for highly-
suspected or macroscopic residual diseases. Since 1992, we have
administered EHRT in patients with pleural dissemination, with 11.2
Gy in 7 fractions or 15 to 16 Gy in 10 fractions after removal of
disseminated lesions in addition to MRT. We treated 52 patients with
MRT alone and 8 with EHRT and MRT. In addition, we gave EHRT
to four patients who developed pleural dissemination later.
Results: For all 60 patients, the overall and cause-specific survival
and local and pleural-dissemination control rates at 5 years were 79,
87, 86, and 69%, respectively. Both Masaoka stage and tumor
resectability were associated with prognosis. In stage IVa patients,
pleural dissemination control rate was 71% at 3 years after EHRT,
whereas it was 49% in patients receiving MRT alone (p  0.38).
Grade 2 or higher radiation pneumonitis was observed in only 3 of
52 patients (5.8%) undergoing MRT initially. In 12 patients who
underwent EHRT, 3 patients (25%) experienced grade 2 or 4
pneumonitis.
Conclusions: Postoperative MRT appeared to prevent local recur-
rence with acceptable toxicity. EHRT is generally safe and may
contribute to control of pleural dissemination.
Key Words: Invasive thymoma, Mediastinal radiotherapy, Entire
hemithorax radiotherapy, Pleural dissemination.
(J Thorac Oncol. 2008;3: 75–81)
Thymomas deriving from the epithelial cells within thethymic gland are pathologically benign but biologically
aggressive,1–3 and so multidisciplinary treatment is often
considered necessary. The treatment strategy has often been
chosen based on the staging system proposed by Masaoka et
al.4,5 The Masaoka stage (shown in Table 1) is considered one
of the most important factors predicting prognosis.6 Masaoka
stage I–II thymomas are associated with excellent prognosis,
and stage III thymoma patients also have favorable progno-
sis.3 On the other hand, stage IVa patients have poor prog-
nosis because of the difficulty in performing complete resec-
tion and giving wide-field radiation therapy. Another
important factor predicting survival seems to be the extent of
surgery.1,5 Recently, several studies have shown that induc-
tion chemotherapy for increasing tumor resectability may
improve the prognosis of advanced thymoma patients.1,2
Thymoma is known as a relatively radiosensitive neoplasm,
and there seems to be a general agreement that postoperative
mediastinal radiotherapy (MRT) should be used in the treat-
ment of invasive thymoma.7,8
For the purpose of improving survival and local control
rates in invasive thymomas, we have used postoperative
MRT in patients with Masaoka stage II–IVb thymoma, in
combination with low-dose entire hemithorax radiotherapy
(EHRT) in patients with pleural dissemination. EHRT has
been suggested to be a therapeutic and prophylactic radio-
therapy technique against pleural dissemination. Uematsu et
al.9,10 treated 23 patients with stage II or III thymoma with
EHRT plus MRT, and obtained excellent 5-year relapse-free
and overall survival rates when compared with those obtained
by MRT alone, advocating the efficacy of EHRT. However,
there are very few other reports on EHRT, and there have
been no prospective studies evaluating EHRT.8–13 Therefore,
the role of EHRT seems to remain controversial. In this study,
we investigated the results of treatment in patients who
received MRT or MRT plus EHRT at our institution.
PATIENTS AND METHODS
Patients
A total of 60 patients with thymoma were treated with
an almost uniform policy regarding radiotherapy in our insti-
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tution between November 1987 and August 2005. There were
23 (38%) men and 37 (62%) women, with a median age of 54
years (range, 21–79 years). We determined Masaoka stage
from findings of preoperative computed tomography and
pathology at surgery. The stage was I or II in 19 (32%)
patients, III in 16 (27%), IVa in 19 (32%), and IVb in 6
(10%). The histopathologic subtype according to the system
proposed by Bernatz et al.14 was available in 50 patients, and
the subtype according to the new World Health Organization
classification proposed in 20003,15 was available in 25. In
three patients, no histologic subtype was obtained. The me-
dian follow-up term was 56 months (range, 1–209 months).
Treatment
Radiation therapy was delivered five times a week after
Masaoka stage, histopathologic classification and tumor re-
sectability were confirmed by either surgical resection or
biopsy. Tumor resectability was defined as shown in Table 2
from grade A (complete resection) to D (biopsy only). The
resectability was grade A in 25 (42%) patients, grade B in 20
(33%), grade C in 9 (15%), and grade D in 6 (10%). All
patients received MRT, without or in combination with
EHRT. The radiation doses of MRT were 30 to 40 Gy in 15
to 20 fractions for stage I or II patients, 40 to 46 Gy in 20 to
23 fractions for patients with highly-suspected microscopic
residuals, 46 to 50 Gy in 23 to 25 fractions for highly-
suspected macroscopic residual diseases, and 50 to 64 Gy in
25 to 32 fractions for gross residual diseases. The average
dose of MRT was 41.4 Gy (range, 30–64 Gy).
EHRT was performed in a total of 12 patients seen in
1992 or later. EHRT was performed after surgical resection
of disseminated lesions immediately before or after MRT in
seven stage IVa patients with highly-suspected microscopic
or macroscopic residuals. Moreover, in one patient with stage
II thymoma, whose tumor ruptured into the thoracic cavity
during surgery, EHRT was performed before MRT. EHRT
was given subsequently against recurrence with pleural dis-
semination in four initially stage III or IVa patients who had
received MRT previously; three initially stage IVa patients
received EHRT after surgical removal of the disseminated
lesions, and one initially stage III patient received EHRT,
followed by boosts to the two disseminated lesions (total 60
Gy) without surgical resection; thus, the pleural disease
before EHRT was macroscopic only in this patient, and it was
microscopic in the remaining 11 patients. The EHRT dose
was 11.2 Gy in 7 fractions in two patients, 15 Gy in 10
fractions in nine, and 16 Gy in 10 fractions in one, with an
average dose of 14.1 Gy. These EHRT doses were deter-
mined considering the tolerance of the lung and taking
previous reports into account.8–13 We considered that these
relatively low doses of radiation would be efficient when the
residual tumor cell number was small. For the 12 patients
undergoing EHRT, an average total dose to the mediastinum
was 44 Gy (range, 30–64 Gy). Figure 1 shows representative
radiation fields for MRT and EHRT.
In 54 patients undergoing tumor resection, 19 (35%)
had preoperative corticosteroid therapy, 11 (20%) had post-
operative steroid therapy, 3 (6%) had preoperative chemo-
therapy, 18 (33%) had intraoperative perfusion thermoche-
motherapy,16 and 3 (6%) had postoperative chemotherapy. In
six patients undergoing only biopsy, five (83%) had steroid
FIGURE 1. Representative radiation fields of
mediastinal radiotherapy [MRT, (A)] and entire
hemithorax radiotherapy [EHRT, (B)].
TABLE 1. Masaoka Stage
Stage I Macroscopically completely encapsulated and
microscopically nocapsular invasion
Stage II 1. Macroscopic invasion into surrounding fatty
tissue or mediastinal pleura, or
2. Microscopic invasion into capsule
Stage III Macroscopic invasion into neighboring organ, ie
pericardium, great vessels, or lung
Stage IVa Pleural or pericardial dissemination
Stage IVb Lymphogenous or hematogenous metastasis
TABLE 2. Tumor Resectability
Grade A Completely resected
Grade B Microscopic residual lesion highly suspected
Grade C Macroscopic residual lesion highly suspected
Grade D Biopsy only
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therapy, and four (67%) had chemotherapy. Table 3 shows
clinical and treatment characteristics of the 60 patients.
Evaluation
Overall and relapse-free survival rates and local and
pleural-dissemination control rates were calculated from the
date of starting radiation therapy. In four patients who re-
ceived EHRT against pleural dissemination developing after
MRT, the time to progression and survival period were
respectively measured from the dates of the first MRT and
secondary EHRT. Overall and cause-specific survival rates,
local control rate, and dissemination control rate were calcu-
lated by the Kaplan–Meier method and differences between
these rates were examined using the log-rank test. Radiation
pneumonitis was classified according to the Radiation Ther-
apy Oncology Group and the European Organization for
Research and Treatment of Cancer acute radiation morbidity
scoring criteria using computed tomography in all cases.
RESULTS
For all 60 patients, the overall survival rate was 79% and
the cause-specific survival rate was 87% at 5 years. The local
control rate was 86% and pleural-dissemination control rate was
69% at 5 years. Figure 2 shows overall survival curves accord-
ing to Masaoka stage, tumor resectability, and radiation field
(MRT alone or MRT plus EHRT). Overall survival rates dif-
fered with Masaoka stage and tumor resectability (p  0.048
and 0.0046, respectively), but not with the radiation field. Re-
spective 2- and 5-year survival rates are shown in Table 4.
Figure 3 shows survival and local and pleural-dis-
semination control rates according to Masaoka stage in 52
patients initially receiving MRT alone. For all 52 patients,
the 5-year overall and cause-specific survival rates were 80
and 87%, respectively, and local and pleural-dissemination
control rates were 84 and 69%, respectively. Cause-spe-
cific survival and local and pleural-dissemination control
rates differed significantly with Masaoka stage.
Figure 4 shows survival and local and dissemination
control rates according to the use of EHRT as an initial treatment
for stage IVa patients. The pleural-dissemination control rate
was relatively high (71% at 3 years) in patients undergoing
EHRT, when compared with 49% in those receiving MRT
alone, although the difference was not significant (p  0.38).
Also, overall and cause-specific survival and local control rates
did not differ significantly between the two groups.
Figure 5 shows overall survival and pleural-dissemina-
tion control curves for 12 patients undergoing EHRT. The
rates were calculated from the date of starting EHRT. Overall
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FIGURE 2. Overall survival curves according
to Masaoka stage (A), tumor resectability (B),
and radiation field (with or without EHRT) (C)
(n  60).
TABLE 3. Patient Characteristics
Total MRT HERT  MRT
No. of patients 60 52 8
Age (yr) median (range) 54 (21–79) 55 (21–79) 49 (33–63)
Gender (male/female) 23/37 20/32 3/5
Masaoka stage
I, II/III/IVa/IVb 19/16/19/6 18/16/12/6 1/0/7/0
Tumor respectability
Grade A/B/C/D 25/20/9/6 25/15/6/6 0/5/3/0
Myasthenia gravis
(Yes/No)
10/50 9/43 1/7
Histology
Bernatz classification
Lymphocytic/
Epithelial
24/5/20/1/10 21/3/17/1/10 3/2/3/0/0
Mixed/Spindled/
Unknown
WHO classification
A/AB/B1/B2/B3/
Unknown
0/2/5/16/2/35 0/2/4/13/0/33 0/0/1/3/2/2
Steroid administration
Yes/No 27/33 21/31 6/2
Chemotherapy
Yes/No 24/36 21/31 3/5
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survival and pleural-dissemination control rates were 80 and
66%, respectively, at 3 years.
Table 4 summarizes 2- and 5-year survival and control
rates according to various prognostic and treatment factors.
Overall, Masaoka stage and resectability appeared to be associ-
ated with patient prognosis, whereas the other factors did not.
In 52 patients receiving MRT alone initially, radiation
pneumonitis was grade 3 in one patient, grade 2 in two, and
grade 1 in 25. In eight patients receiving EHRT and MRT
initially, radiation pneumonitis was grade 4 in one patient, grade
2 in one, and grade 1 in four. In 12 patients undergoing EBRT
(including four patients receiving EBRT at intervals after MRT),
radiation pneumonitis was grade 4 in one patient, grade 2 in two,
and grade 1 in seven. One patient receiving approximately 40
Gy to the spinal cord developed radiation myelopathy. No
patient died of adverse effects of radiotherapy.
DISCUSSION
Although invasive thymomas are relatively common
among mediastinal tumors, their incidence is generally low,
and so it is difficult to carry out prospective randomized
studies on treatment of invasive thymoma with sufficient
numbers of patients. We therefore evaluated the efficacy of
radiation therapy retrospectively. Masaoka stage and the
extent of surgical resection are known to be associated with
patient prognosis.1,4,5 In all 60 patients in our study, Masaoka
stage and tumor resectability were associated with overall
survival rates. Pleural-dissemination control rate was also
dependent on Masaoka stage in 52 patients undergoing MRT
alone as initial radiotherapy.
After MRT, we have obtained favorable survival and
local control rates. Local control was excellent in patients
with grade A or B resectability, and it was also fair in those
with grade C resectability (highly-suspected macroscopic
residuals). Overall and cause-specific survival rates for all
stages of thymoma patients in the present study compare
favorably with those reported previously5,6,13 In view of the
acceptable toxicity after MRT, our results would support the
usefulness of MRT in the multidisciplinary treatment of
thymoma. In completely resected stage I–II thymoma, how-
ever, a few studies suggested that radiation therapy might not
be necessary.17,18 Although our results of postoperative MRT
in stage I–II patients including those with grade B respect-
ability are not inferior to those obtained by surgery alone,17,18
TABLE 4. Survival and Control Rates (%)
n
Overall Survival Cause-specific Survival Local Control Dissemination Control
2-yr 5-yr p 2-yr 5-yr p 2-yr 5-yr p 2-yr 5-yr p
Total 60 95 79 98 87 92 86 83 69
Masaoka Stage 0.048 0.013 0.079 0.0045
I–II 19 100 94 100 100 100 100 100 100
III 16 100 82 100 89 94 83 75 61
IVa 19 90 64 95 73 84 72 66 39
IVb 6 83 63 100 75 80 80 100 53
Tumor resectability 0.0046 0.0001 0.00019 0.0011
A 25 96 78 100 89 96 91 92 87
B 20 100 94 100 100 100 100 85 68
C 9 89 76 100 86 88 66 50 0
D 6 83 ––* 83 ––* 50 ––* 80 ––*
Initial radiation 0.22 0.18 0.34 0.94
MRT only 52 94 80 98 87 90 84 84 69
EHRTMRT 8 100 71 100 83 100 100 75 75
Age (yr) 0.22 0.19 0.16 0.16
60 21 91 70 100 92 95 95 95 89
60 39 97 83 97 83 90 81 76 59
Gender 0.13 0.05 0.30 0.43
Female 37 95 74 97 82 89 84 83 71
Male 23 96 85 100 94 96 90 82 67
Myasthenia gravis 0.78 0.83 0.76 0.98
Yes 10 100 88 100 100 90 90 80 67
No 50 94 77 98 84 92 85 83 70
Steroid administration 0.21 0.14 0.12 0.022
Yes 27 89 63 96 72 81 81 71 61
No 33 100 89 100 96 100 92 91 76
Chemotherapy 0.85 0.57 0.24 0.17
Yes 24 92 78 96 81 83 77 77 56
No 36 97 79 100 91 97 92 86 79
*Not assessable.
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FIGURE 3. Overall survival (A),
cause-specific survival (B), local con-
trol (C), and pleural-dissemination
control (D) curves for patients un-
dergoing MRT as an initial radiation
treatment (n  52).
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FIGURE 4. Overall survival (A),
cause-specific survival (B), local con-
trol (C), and pleural-dissemination
control (D) curves for stage IVa pa-
tients undergoing MRT (n  12) or
MRT  EHRT (n  7).
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the role of MRT should be further clarified in this group of
patients.
EHRT appeared to be feasible in terms of safety. In 12
patients who received EHRT, one patient developed grade 4
radiation pneumonitis, but this appeared to be in part related
to operative procedure. The remaining 11 patients did not
have severe complications. No patients died of complications
after EHRT. Uematsu et al.9,10 reported the safety of EHRT
with 10 to 16 Gy in 10 to 16 fractions. In the present study,
EHRT with doses up to 15 Gy given in 10 fractions seems to
be generally safe. Uematsu et al.9,10 reported 100% relapse-
free survival at 3 years after EHRT plus MRT in stage II or
III patients. Although most of our 12 patients undergoing
EHRT had pleural dissemination, they had a relatively high
pleural-dissemination control rate of 66% at 3 years after
EHRT. Although it is difficult to draw definite conclusions
from the present study comprising the small patient number,
it may be possible that EHRT contributes to improved dis-
semination control rates when it is given after macroscopic
total removal of disseminated lesions.
Combined multidisciplinary treatment of advanced thy-
momas is a topic in recent years. Several studies indicate that
induction chemotherapy to optimize surgical resectability and
consolidation chemotherapy to control residual disease may
improve the prognosis of patients with advanced thymo-
mas.1,2,19–22 In the present study, EHRT appeared to play a
role in eradicating pleural dissemination in patients with stage
IVa thymoma, but the patients who received EHRT did not
undergo intensive chemotherapy. Cure may be achieved more
effectively in patients with pleural dissemination when EHRT
plus MRT and induction or consolidation chemotherapy are
given in combination with surgery. However, it is feared that
the risk of severe complications might increase in patients
who undergo both EHRT and chemotherapy. Therefore, we
suggest that patients who should undergo EHRT and induc-
tion or consolidation chemotherapy need to be selected care-
fully by applying eligibility criteria (e.g., age, performance
status, adequate bone marrow reserve, liver and renal func-
tion). The fact that one of the patients receiving EHRT
developed severe radiation pneumonitis indicates safer treat-
ment is more ideal. Moreover, recent studies cautioned the
risk of radiation pneumonitis when large volumes of lungs
were irradiated with relatively low doses.23–25 So we are
planning “whole pleural radiation ” with an intensity-modu-
lated radiation therapy technique26 using helical tomo-
therapy27 to reduce the lung dose, in place of EHRT.
CONCLUSIONS
Postoperative MRT appeared to play a role in prevent-
ing local recurrence with acceptable toxicity. EHRT with
doses up to 15 Gy appeared to be generally safe, but caution
should be made with respect to occurrence of high-grade
toxicity. EHRT may possibly improve outcome for stage IVa
disease or recurrence with pleural dissemination. We will try
to clarify in future collaborative studies whether EHRT con-
tributes to control of pleural dissemination and improvement
of survival rate. It is expected that new radiation technique
like intensity-modulated radiation therapy would improve the
outcome by increasing the dose and reducing the possibility
of radiation pneumonitis. At present, we recommend EHRT
for patients with nonextensive dissemination and good post-
operative pulmonary function in the combined multidisci-
plinary treatment.
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